Checkpoint
Data Breaches, Cyber Attacks and Security Report

https://checkpointtx.com  ᛫ 
Last updated November 12, 2019

About Checkpoint

Company Overview

Checkpoint Therapeutics, Inc. (�Checkpoint�) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (�NSCLC�). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-na�ve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

Valuation

Employees

CEO

Location

Data Breaches and Security News

Checkpoint Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Checkpoint is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Checkpoint

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Checkpoint's security performance with other companies